Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Alkermes (ALKS) was upgraded by Truist Financial Corporation to "strong-buy".
Alkermes (ALKS) had its price target lowered by Piper Sandler from $45.00 to $43.00. They now have an "overweight" rating on the stock.
Alkermes (ALKS) was downgraded by Zacks Research from "hold" to "strong sell".
Alkermes CEO Pops Calls 2026 a “Really Exciting Year” as Orexin Agonists Near Narcolepsy Launch [Yahoo! Finance]